nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.05.2011 | Review Article

Three-dimensional radiobiological dosimetry (3D-RD) with ¹²⁴I PET for ¹³¹I therapy of thyroid cancer

verfasst von: George Sgouros, Robert F. Hobbs, Francis B. Atkins, Douglas Van Nostrand, Paul W. Ladenson, Richard L. Wahl

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, ¹²⁴I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of ¹²⁴I PET/CT on thyroid cancer therapy.

Hellman S, Devita VT, Rosenberg SA. Principles of cancer management: radiation therapy. Cancer: principles & practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 265–88.

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214.PubMedCrossRef

Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002;12(2):121–34.PubMedCrossRef

Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid 2005;15(12):1321–31.PubMedCrossRef

Driedger AA, Quirk S, McDonald TJ, Ledger S, Gray D, Wall W, et al. A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure. Clin Nucl Med 2006;31(8):454–7.PubMedCrossRef

Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366–72.PubMed

Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37(5):884–95.PubMedCrossRef

Chiavassa S, Aubineau-Lanièce I, Bitar A, Lisbona A, Barbet J, Franck D, et al. Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code. Phys Med Biol 2006;51(3):601–16.PubMedCrossRef

Flux GD, Webb S, Ott RJ, Chittenden SJ, Thomas R. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging. J Nucl Med 1997;38(7):1059–66.PubMed

10.

Furhang EE, Chui CS, Kolbert KS, Larson SM, Sgouros G. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys 1997;24(7):1163–72.PubMedCrossRef

11.

Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med 1997;38(2):301–8.PubMed

12.

Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 1997;80(12 Suppl):2591–610.PubMedCrossRef

13.

Tagesson M, Ljungberg M, Strand SE. A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system. Acta Oncol 1996;35(3):367–72.PubMedCrossRef

14.

Sgouros G, Kolbert KS, Zaidi H. The three-dimensional internal dosimetry software package, 3D-ID. In: Therapeutic applications of Monte Carlo calculations in nuclear medicine. Philadelphia: Institute of Physics; 2002.

15.

Kolbert KS, Pentlow KS, Pearson JR, Sheikh A, Finn RD, Humm JL, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med 2007;48(1):143–9.PubMed

16.

Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, et al. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med 1990;31(11):1884–91.PubMed

17.

Mohan R, Barest G, Brewster LJ, Chui CS, Kutcher GJ, Laughlin JS, et al. A comprehensive three-dimensional radiation treatment planning system. Int J Radiat Oncol Biol Phys 1988;15(2):481–95.PubMedCrossRef

18.

Prideaux AR, Song H, Hobbs RF, He B, Frey EC, Ladenson PW, et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med 2007;48(6):1008–16.PubMedCrossRef

19.

Fowler JF. 21 years of biologically effective dose. Br J Radiol 2010;83(991):554–68.PubMedCrossRef

20.

O’Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med 1999;40(8):1337–41.PubMed

21.

Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm 2004;19(3):363–70.PubMedCrossRef

22.

Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20(1):47–51.PubMedCrossRef

23.

Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985;58(690):515–28.PubMedCrossRef

24.

Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys 2008;35(3):1123–34.PubMedCrossRef

25.

Hobbs RF, Sgouros G. Calculation of the biological effective dose for piecewise defined dose-rate fits. Med Phys 2009;36(3):904–7.PubMedCrossRef

26.

Hobbs RF, Wahl RL, Lodge MA, Javadi MS, Cho SY, Chien DT, et al. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med 2009;50(11):1844–7.PubMedCrossRef

27.

Zaider M, Hanin L. Biologically-equivalent dose and long-term survival time in radiation treatments. Phys Med Biol 2007;52(20):6355–62.PubMedCrossRef

28.

Freudenberg LS, Jentzen W, Müller SP, Bockisch A. Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging 2008;35(3):502–8.PubMedCrossRef

29.

Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, Larson SM, Sgouros G. Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia. J Nucl Med 2001;42(1):27–32.PubMed

30.

Stabin MG, Sparks RB. OLINDA: PC-based software for biokinetic analysis and internal dose calculations in nuclear medicine. J Nucl Med 2003;44(5):103P.

31.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46(6):1023–7.PubMed

32.

Amro H, Wilderman SJ, Dewaraja YK, Roberson PL. Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with ¹³¹I-tositumomab therapy. J Nucl Med 2010;51(4):654–9.

33.

Dewaraja YK, Schipper MJ, Roberson PL, et al. ¹³¹I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med 2010;51(7):1155–62.

34.

Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33(6):1132–6.PubMed

35.

Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 1976;03(04):253–5.PubMedCrossRef

Titel: Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer
verfasst von: George Sgouros
Robert F. Hobbs
Francis B. Atkins
Douglas Van Nostrand
Paul W. Ladenson
Richard L. Wahl
Publikationsdatum: 01.05.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe Sonderheft 1/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1769-1

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2011

Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

The production of [124I]iodine and [86Y]yttrium

Preclinical animal research on therapy dosimetry with dual isotopes

Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer

Quantitative imaging of 124I and 86Y with PET

Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies